KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 152 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $255,000 | +0.4% | 67,929 | +9.6% | 0.01% | -25.0% |
| Q1 2018 | $254,000 | -14.8% | 62,000 | -3.1% | 0.01% | 0.0% |
| Q4 2017 | $298,000 | -34.4% | 64,000 | 0.0% | 0.01% | -52.9% |
| Q3 2017 | $454,000 | -1.9% | 64,000 | 0.0% | 0.02% | -15.0% |
| Q2 2017 | $463,000 | +15.8% | 64,000 | -1.5% | 0.02% | +25.0% |
| Q1 2017 | $400,000 | +6.7% | 65,000 | +1.6% | 0.02% | -11.1% |
| Q4 2016 | $375,000 | +10.3% | 64,000 | 0.0% | 0.02% | -14.3% |
| Q3 2016 | $340,000 | -21.7% | 64,000 | -2.5% | 0.02% | -38.2% |
| Q2 2016 | $434,000 | -16.2% | 65,610 | -40.9% | 0.03% | +47.8% |
| Q1 2016 | $518,000 | -7.7% | 111,000 | 0.0% | 0.02% | -41.0% |
| Q4 2015 | $561,000 | +43.5% | 111,000 | 0.0% | 0.04% | +129.4% |
| Q3 2015 | $391,000 | -21.6% | 111,000 | +122.0% | 0.02% | -15.0% |
| Q2 2015 | $499,000 | +17.4% | 50,000 | +66.7% | 0.02% | +33.3% |
| Q4 2014 | $425,000 | +132.2% | 30,000 | +112.8% | 0.02% | +275.0% |
| Q4 2013 | $183,000 | – | 14,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,605,800 | $16,026,000 | 4.65% |
| Baupost Group | 25,791,678 | $257,401,000 | 4.29% |
| 1492 Capital Management LLC | 264,297 | $2,638,000 | 1.67% |
| Cormorant Asset Management, LP | 826,000 | $8,243,000 | 1.10% |
| FALCON POINT CAPITAL, LLC | 251,137 | $2,506,000 | 0.85% |
| OAK RIDGE INVESTMENTS LLC | 3,291,711 | $32,851,000 | 0.70% |
| Knoll Capital Management, LLC | 200,000 | $1,996,000 | 0.64% |
| Rhenman & Partners Asset Management AB | 534,000 | $5,329,000 | 0.64% |
| Old West Investment Management, LLC | 79,667 | $795,000 | 0.55% |
| THREE BAYS CAPITAL LP | 1,284,000 | $12,814,000 | 0.53% |